Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a null hypothesis study. The investigators hypothesize that there will be no difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute intervals after administration of either surfactant and there will be no differences in the number of doses needed between the two surfactants in premature infants admitted to our NICU.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan
• Collaborators: Cornerstone Pharmaceuticals, Inc.; Rafael Pharmaceuticals Inc.
• Treatments: Beractant; Poractant alfa

Criteria

Inclusion Criteria:

• Preterm infants between 28 and 31 6/7 weeks' gestational age

• Inborn to UM NICU

• < 12 hours of age

• Respiratory Distress Syndrome

• radiographic evidence

• need for endotracheal intubation

• Oxygen requirement > 30% FiO2

• Decision to give surfactant by the treatment team

Exclusion Criteria:

• Major congenital anomaly

• Sepsis syndrome in extremis